

**REGISTERED CHARITY NUMBER: SC049399**

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025  
FOR  
SEPSIS RESEARCH (FEAT) SCIO**

Armstrong Watson LLP  
Caledonia House  
89 Seaward Street  
Glasgow  
G41 1HJ

**SEPSIS RESEARCH (FEAT) SCIO**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 7
<b>Independent Examiner's Report</b>	8
<b>Statement of Financial Activities</b>	9
<b>Balance Sheet</b>	10
<b>Notes to the Financial Statements</b>	11 to 18

## SEPSIS RESEARCH (FEAT) SCIO

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their report with the financial statements of the charity for the year ended 31 March 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### OBJECTIVES AND ACTIVITIES

##### Objectives and aims

##### Our Vision

To Stop Sepsis Now

##### Our Mission

To save lives and improve outcomes in sepsis patients by funding research and raising awareness.

##### Our Strapline

Saving lives today. Funding research for tomorrow.

##### What is Sepsis?

Sepsis arises when the body's response to an infection spirals rapidly out of control, damaging its own tissues and organs. Any type of infection can lead to sepsis and despite advanced medical care, sepsis can swiftly cause shock, failure of multiple organs, and death.

- In the UK, Sepsis impacts around 246,000 people each year, with around 50,000 losing their lives - equivalent to 5 deaths every hour.
- Each year, 25,000 children in the UK are diagnosed with Sepsis.
- Sepsis causes more deaths annually in the UK than breast, bowel, and prostate cancer combined.
- Globally, sepsis impacts 49 million people annually and leads to 11 million deaths, exceeding the mortality rate of cancer. It is the leading cause of preventable death worldwide.
- Around 50% of sepsis survivors experience long-term physical and/or psychological effects, such as limb loss or PTSD.

#### ACHIEVEMENT AND PERFORMANCE

##### Charitable activities

##### Performance

##### Progress towards our strategic objectives

Sepsis Research FEAT has made significant strides towards its strategic objectives over the past year, building on its commitment to advancing sepsis research, fostering collaboration, and increasing public awareness.

##### **1. Provide research funding and Patient & Public Involvement (PPI) in order to understand sepsis better, to develop specific treatments and to save lives.**

##### Completion of the Sepsis Priority Setting Partnership (PSP)

We successfully completed the Sepsis Priority Setting Partnership (PSP) in collaboration with key stakeholders and members of the sepsis community. This important initiative identified the top 10 research priorities for sepsis, providing a roadmap for future research efforts. The findings were published in the prestigious journal *Lancet Respiratory*, ensuring wide dissemination within the medical and research communities.

##### Funding Groundbreaking Sepsis Research

Sepsis Research FEAT continued to prioritise funding innovative research projects that align with the priorities identified through the PSP. In partnership with the Rosetree Foundation and other partners we funded:

- ██████████ (University College London): Awarded £20,000 to investigate the antimicrobial properties of serum in sepsis, a study that holds potential for developing new therapeutic strategies.
- ██████████ (University of Birmingham): Received £19,768 to develop a novel strategy aimed at reducing inflammation-driven clotting in sepsis, a key contributor to the severity of the condition.

These grants demonstrate our ongoing commitment to fostering high-quality research that can lead to better outcomes for sepsis patients.

## SEPSIS RESEARCH (FEAT) SCIO

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

#### Charitable activities - continued

##### Public and Patient Involvement & Engagement (PPIE)

We have established a comprehensive Public and Patient Involvement & Engagement (PPIE) strategy, recognising the importance of incorporating patient voices into research. To support this, we now offer researchers access to a pool of PPI participants for a fee, ensuring a sustainable model for involving patients in shaping sepsis research.

Sepsis Research FEAT is proud to have provided PPIE support for the work of ██████████ ██████████ at the University of Glasgow's College of Medical, Veterinary & Life Sciences, School of Infection and Immunity. Their Sepsis Treatment by Targeting Antibiotic Released Bacterial Proteins (STTAR-BacPro) project seeks to develop safe treatments to block toxic factors released during antibiotic treatment of bacterial infections.

We are pleased to support PPIE activities for ██████████ ██████████ at Newcastle University. Her research focuses on understanding immune function recovery after hospitalisation for sepsis. This vital work explores the long-term impacts of sepsis on the immune system, aiming to develop strategies that improve patient outcomes and quality of life post-discharge.

We further supported a study being led by ██████████ ██████████ of the University of Cambridge, focusing on understanding how people recover from critical illnesses such as sepsis providing them with PPIE support. Recovery from sepsis is known to vary from person to person. The goal of this project is to create more personalised care that better supports individuals and families.

Through these initiatives, Sepsis Research FEAT continues to support innovative research that aligns with our mission to improve the lives of those affected by sepsis.

Additionally, we supported the GenOMICC study, which focuses on the genetic mechanisms of critical illness, by funding PPI activities with £17,200. This work underscores the value of patient insights in advancing research and improving clinical outcomes.

##### Recruitment of a Medical Director

We were delighted to welcome ██████████ ██████████ as our new Medical Director. ██████████ ██████████ brings extensive expertise in sepsis and critical care, strengthening the charity's ability to shape and influence research priorities and clinical practices. His appointment marks a significant step in our goal to enhance the charity's medical leadership and impact.

##### Future Focus

These achievements reflect our progress toward achieving our strategic objectives, including advancing research, raising awareness, and fostering collaboration. As we move forward, Sepsis Research FEAT remains committed to ensuring that our efforts continue to have a lasting impact on understanding and addressing sepsis.

## **2. Raise awareness of sepsis across the UK**

Sepsis Research FEAT has continued to expand its efforts to raise awareness of sepsis and its research initiatives across the UK, making significant strides in elevating visibility. A key milestone this year was the launch of our key research priorities in The Lancet Respiratory Medicine during Sepsis Awareness Month in September, ensuring the findings reached a global audience of researchers, clinicians, and the public.

We welcomed a new ambassador to our team, enhancing our ability to engage with diverse audiences and amplify our messaging. Our awareness efforts included a winter illness campaign delivered in Liverpool, supported through a generous corporate donation, further highlighting the dangers of sepsis during peak illness seasons.

## SEPSIS RESEARCH (FEAT) SCIO

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

#### Charitable activities - continued

Social media remained a cornerstone of our outreach, with targeted activity designed to engage audiences and drive traffic to our website. To strengthen our digital presence, we partnered with a new marketing agency to develop and deliver impactful campaigns while improving the SEO of our website to make vital information more accessible.

Our team actively engaged with the research and wider community, speaking at numerous research conferences and delivering talks to community groups, further embedding sepsis awareness into public and professional conversations. This year also saw an increase in mass media coverage, with the charity featured across TV, radio, and newspapers, significantly broadening our reach and impact.

Raising awareness of sepsis and highlighting the charity's research initiatives remain central to our mission. These efforts reflect our commitment to ensuring sepsis is widely recognised, understood, and prioritised as a public health issue.

#### 3. Shaping policy

Sepsis Research FEAT has continued to influence health policy across the UK, ensuring that sepsis remains a key priority for decision-makers. The charity has maintained strong relationships with the Scottish Government, engaging with key stakeholders and policymakers to keep sepsis research and awareness at the forefront of health discussions. This year, new connections were established through meetings with ██████████ MSP, further strengthening efforts in Scotland.

The charity also contributed to the NHS Change Debate, providing valuable input to help shape a health service that is fit for the future and prioritises sepsis research and awareness. In Northern Ireland, engagement with ██████████ MP marked an important step in expanding efforts to an area where sepsis awareness has been underrepresented.

Sepsis Research FEAT remains dedicated to fostering stronger connections with both the Scottish and UK governments. A central focus is promoting a UK-wide Sepsis Awareness Campaign, drawing on insights and successes from previous Scottish campaigns. By aligning national policies and ensuring consistent messaging, the charity aims to make sepsis awareness a priority across all four nations of the UK. These policy efforts reflect Sepsis Research FEAT's commitment to driving change and improving outcomes for those affected by sepsis.

#### 4. Tell sepsis stories through the eyes of people affected by it

This year, the charity published 26 new personal stories from individuals affected by sepsis, aiming to enhance awareness of its symptoms and the importance of the research we support. We also featured the experiences of public figures and celebrities impacted by sepsis, helping to broaden understanding of its potentially devastating effects and reaching a wider audience.

Supporters increasingly shared their experiences in their own words through short video clips, fostering a more personal connection with audiences. This approach has attracted new followers on social media platforms such as TikTok and LinkedIn, marking a significant step forward in engaging with younger and more diverse audiences.

Our In Memory Campaign deeply resonated with supporters, achieving strong engagement across all social media platforms. The combination of impactful social media initiatives and increased mainstream media coverage has significantly elevated the charity's profile and boosted awareness of sepsis.

These efforts, paired with high standards of supporter stewardship, have resulted in stronger engagement from our community, helping to build momentum for the charity's mission to save lives through research and awareness.

## SEPSIS RESEARCH (FEAT) SCIO

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

#### ACHIEVEMENT AND PERFORMANCE

##### Fundraising and income generation

The past year has presented significant challenges for income generation. The cost-of-living crisis, economic uncertainty, and new government policies have impacted progress towards our income targets. Despite these challenges, income from our community fundraising and trusts has remained resilient.

Community fundraising continues to grow, with an increasing number of individuals participating in events and challenges. However, the average amount raised per individual has decreased by approximately 20%, a trend we expect to continue in the short term.

Our relationships with trust funders remain strong, but the competitive landscape has intensified. While donations from trusts have plateaued, they remain a vital source of income for the charity.

This year, the organisation invested in developing a more strategic approach to securing corporate funding. Although projected income from this initiative did not materialise within the year, the groundwork has been established, and we anticipate new revenue streams in the next financial year.

The trustees are committed to further diversifying and strengthening the charity's fundraising portfolio. During the coming year, there will be a particular focus on developing legacy giving and major donor programmes. These are long-term strategies, and while income from these areas will take time to materialise, they are designed to provide stability and mitigate fluctuations in our existing funding sources.

The board would like to express its sincere gratitude to everyone who has supported the charity this year. Your contributions enable us to continue our vital work.

##### Volunteering

- The Sepsis Research FEAT Action Team on Facebook grew to 170 members, who support the charity through ad hoc volunteering requests.
- [REDACTED] joined as the charity's third ambassador. [REDACTED] has provided extensive support to bereaved families and helped raise awareness following the death of her son Dylan from sepsis in 2018.
- Ambassador Kim Smith actively promoted sepsis awareness throughout the year via TikTok, Instagram, and in-person talks to community groups and clinicians.
- Ambassador [REDACTED] helped expand the charity's network and engaged high-profile supporters. She created a collaborative Instagram reel for the Mother's Day 2025 maternal sepsis campaign, which became one of the charity's best-performing posts. She also participated in the final workshop of the sepsis research priority setting exercise in Cambridge.
- Many other individuals contributed time and expertise to Patient & Public Involvement & Engagement (PPIE) work linked to research studies in 2024/25. The charity has increased its focus on this important area.

#### FINANCIAL REVIEW

##### Financial position

For the year ending 31st March 2025, the charity's total income from all sources was £351,649 (2024: £371,421) as outlined in the attached financial statements. There is a net deficit for the year 2024/25 of £6,713 (compared to a surplus in 2024 of £18,006).

Expenditure on charitable activities this year totalled £279,075 (2024: £291,919) which represents 78% of our total expenditure. The team and trustees continue to strictly manage the charity's expenses. There was an increase in fundraising costs due to an increase in hours worked by freelance fundraisers than in previous years. This is part of the charity's strategy to expand and strengthen its fundraising efforts across the UK.

For every £1 raised 73p goes towards our charitable aims.

## **SEPSIS RESEARCH (FEAT) SCIO**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025**

#### **FINANCIAL REVIEW**

##### **Reserves policy**

The reserves policy ensures the charity maintains cash reserves equivalent to approximately three months of operational costs. This provides a buffer to manage the timing between income receipt and expense commitments while safeguarding funds for the charity's quarterly obligations to research partners. The current free reserve is £137,858, and the Trustees are comfortable that the existing policy is being met. Should the charity need to wind up, any remaining funds will be transferred to a charitable organisation with aligned aims and values.

##### **Going concern**

The trustees are confident that the charity remains a going concern, with sufficient reserves to ensure its viability for the foreseeable future. Regular reviews of detailed budgets and management accounts support this position.

The board has approved the 2025/26 income budget, which projects an increase of 11% compared to the previous year, excluding any exceptional income secured during the year. The trustees and management team are optimistic about meeting income targets and sustaining planned expenditures.

If circumstances change, a contingency plan is in place to manage potential variations. Trustees are assured that the charity's prudent financial management and focus on preserving cash flow will enable it to continue funding vital research and adapt to future challenges.

#### **THE YEAR AHEAD - WHAT WE INTEND TO ACHIEVE**

In 2025/26 Sepsis Research FEAT plans to:

##### **Provide further funding for research and Patient & Public Involvement (PPI)**

- Provide additional funding to the GenOMICC study to cover second year of PPI involvement
- Fund the UK arm of DALI2 research - Defining Antibiotic Levels in Intensive care patients
- Mapping exercise to find all the medics who undertake sepsis research and can undertake the priorities as identified in the research priority setting document
- Further enhance our partnership with the Rosetree Foundation - funding at least 2 research projects
- Create a funding call inviting applications from researchers

##### **Raise sepsis awareness across the UK**

- Run several campaigns throughout the UK with a focus on maternal sepsis
- Create, deliver and evaluate a sepsis awareness campaign in Northern Ireland
- Multi-media awareness campaigning during Sepsis Awareness Month
- Collaborations with ambassadors and influencers to generate sepsis awareness

##### **Shape policy and decision-making involving sepsis**

- Continue to influence policy-making via collaboration with senior health professionals and government officials - to guarantee the adoption of best practice and enhancements in patient care.
- Hold a sepsis awareness event at Stormont
- Campaign for improved statistical data and consistent publication of this information.

##### **Tell sepsis stories through the eyes of people affected by it**

- Engage with patients and families with lived experience of sepsis to share their stories and raise awareness
- Use social and mainstream media to share stories and updates on sepsis research

## **SEPSIS RESEARCH (FEAT) SCIO**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025**

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Governing document**

Sepsis Research FEAT is a Scottish Charitable Incorporated Organisation (SCIO) registered and regulated by the Office of the Scottish Charity Regulator (OSCR). Established in Scotland, Sepsis Research FEAT operates as a cross-border charity, conducting activities across the United Kingdom.

Under current legislation, charities established under Scottish law are not required to register with the Charity Commission for England and Wales. As such, Sepsis Research FEAT is solely regulated by OSCR while being free to operate in England, Wales and Northern Ireland without additional regulatory obligations. This framework ensures compliance with Scottish charity law while allowing us to pursue our mission throughout the UK.

The charity's structure, governance, and management are outlined in its constitution, which is regularly reviewed by the board of trustees.

It actively engages skilled freelance professionals, whose expertise is essential for driving income generation, managing research initiatives, and delivering awareness campaigns.

The organisation maintains strong connections with key partners, including the Scottish Government Patient Safety team and the European Sepsis Alliance, and is a founding partner of the Global Sepsis Alliance.

##### **Recruitment and appointment of new trustees**

As part of the trustee rotation process commencing in 2025/26, the board has welcomed three new trustees. Each new trustee has undergone a structured induction programme, including training to ensure they are fully equipped to fulfil their responsibilities.

The newly recruited trustees meet the charity's criteria, bringing professional expertise from medical, business, or related fields, or personal experience of sepsis. The board remains committed to recruiting additional trustees throughout the year to address any gaps in skills or experience and strengthen the charity's governance.

##### **Management**

The trustees meet regularly to oversee the charity's management. Day-to-day operations are led by the Chief Operating Officer, Colin Graham, who is also a director at Colin Graham Associates and manages a team of freelance professionals.

##### **Wider network**

The charity has associations with the Scottish Government Patient Safety team, the European Sepsis Alliance and Global Sepsis Alliance as a founding member. We work with universities including Edinburgh, Glasgow, Strathclyde & University of Cambridge. New partnership programmes with institutions UK-wide are constantly under consideration.

##### **Risk management**

The trustees play a key role in managing risk, particularly during times of uncertainty. While the charity's strategic vision incorporates an element of calculated risk, the board and its three subcommittees meet quarterly to evaluate these risks and, when needed, consult external expertise to inform their decisions.


##### **Key management personnel**

The Trustees consider that the Board of Trustees and the Chief Operating Officer comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day-to-day basis. None of the Trustees are remunerated for their roles as Trustees.

#### **REFERENCE AND ADMINISTRATIVE DETAILS**


##### **Registered Charity number**

SC049399



**SEPSIS RESEARCH (FEAT) SCIO**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 MARCH 2025**




**Independent Examiner**

  
Armstrong Watson LLP  
Caledonia House  
89 Seaward Street  
Glasgow  
G41 1HJ

**Chief Operating Officer**



Approved by order of the board of trustees on 27 May 2025 and signed on its behalf by:



## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF SEPSIS RESEARCH (FEAT) SCIO**

I report on the accounts for the year ended 31 March 2025 set out on pages nine to eighteen.

### **Respective responsibilities of trustees and examiner**

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The charity's trustees consider that the audit requirement of Regulation 10(1)(a) to (c) of the Accounts Regulations does not apply. It is my responsibility to examine the accounts as required under Section 44(1)(c) of the Act and to state whether particular matters have come to my attention.

### **Basis of the independent examiner's report**

My examination was carried out in accordance with Regulation 11 of the Charities Accounts (Scotland) Regulations 2006. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently I do not express an audit opinion on the view given by the accounts.


### **Independent examiner's statement**

In connection with my examination, no matter has come to my attention :

- (1) which gives me reasonable cause to believe that, in any material respect, the requirements
  - to keep accounting records in accordance with Section 44(1)(a) of the 2005 Act and Regulation 4 of the 2006 Accounts Regulations; and
  - to prepare accounts which accord with the accounting records and to comply with Regulation 8 of the 2006 Accounts Regulations

have not been met; or

- (2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Armstrong Watson LLP  
Caledonia House  
89 Seaward Street  
Glasgow  
G41 1HJ

27 May 2025

**SEPSIS RESEARCH (FEAT) SCIO****STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
<b>INCOME FROM</b>					
Donations and legacies	2	269,296	79,892	349,188	369,383
Other trading activities	3	888	-	888	1,576
Investment income	4	1,573	-	1,573	462
<b>Total</b>		<u>271,757</u>	<u>79,892</u>	<u>351,649</u>	<u>371,421</u>
<b>EXPENDITURE ON</b>					
Raising funds	5	79,287	-	79,287	61,496
<b>Charitable activities</b>	6				
Charitable activities		222,683	56,392	279,075	291,919
<b>Total</b>		<u>301,970</u>	<u>56,392</u>	<u>358,362</u>	<u>353,415</u>
<b>NET INCOME/(EXPENDITURE)</b>		<b>(30,213)</b>	<b>23,500</b>	<b>(6,713)</b>	<b>18,006</b>
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		168,071	-	168,071	150,065
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>137,858</u>	<u>23,500</u>	<u>161,358</u>	<u>168,071</u>

**CONTINUING OPERATIONS**


All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**SEPSIS RESEARCH (FEAT) SCIO****BALANCE SHEET  
31 MARCH 2025**

	<b>Notes</b>	<b>2025 £</b>	<b>2024 £</b>
<b>CURRENT ASSETS</b>			
Debtors	11	<b>1,137</b>	229
Cash at bank		<b>163,988</b>	171,173
		<u><b>165,125</b></u>	<u>171,402</u>
<b>CREDITORS</b>			
Amounts falling due within one year	12	<b>(3,767)</b>	(3,331)
		<u><b>161,358</b></u>	<u>168,071</u>
<b>NET CURRENT ASSETS</b>			
		<u><b>161,358</b></u>	<u>168,071</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			
		<u><b>161,358</b></u>	<u>168,071</u>
<b>NET ASSETS</b>			
		<u><b>161,358</b></u>	<u>168,071</u>
<b>FUNDS</b>	14		
Unrestricted funds		<b>137,858</b>	168,071
Restricted funds		<b>23,500</b>	-
		<u><b>161,358</b></u>	<u>168,071</u>
<b>TOTAL FUNDS</b>		<u><b>161,358</b></u>	<u>168,071</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 27 May 2025 and were signed on its behalf by:



**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities and Trustee Investment (Scotland) Act 2005.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The financial statements are presented in Sterling (£).

**Going concern**

The financial statements have been prepared on a going concern basis which the Trustees believe to be appropriate for the reasons set out in the Trustees' Report.

**Financial reporting standard 102 - reduced disclosure exemptions**

The charity has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

The value of donated services provided to the charity are recognised at their open market value in the period in which they are receivable as incoming resources, where the benefit to the charity can be reliably measured. An equivalent amount is included as expenditure under the relevant heading in the Statement of Financial Activities.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Raising funds**

Raising funds includes all expenditure incurred by the charity to raise funds for its charitable purposes and includes costs of all fundraising activities and events.

**Charitable activities**

Costs of charitable activities are incurred on the charity's provision of sepsis awareness, including support costs and costs relating to the governance of the charity.

**Governance costs**

Consists of the costs of the accounts preparation and other financial services and any expenditure incurred in compliance with the legal requirements of the charity.

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025**

**1. ACCOUNTING POLICIES - continued**

**Allocation and apportionment of costs**

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel and governance costs which support the charity's programmes and activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities.

**Taxation**

The charity is exempt from tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the Trustees.

Designated funds are set aside by the trustees out of unrestricted general funds for specific future purposes or projects.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Financial instruments**

The charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable.

Debt instruments that are payable or receivable within one year, typically trade or other accounts receivable and payable, are measured, initially and subsequently, at the undiscounted amount of cash or other consideration expected to be paid or received.

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment and if found, an impairment loss is recognised in profit or loss.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities.

**Provisions**

Provisions are recognised when the charity has a legal or constructive obligation at the reporting date as a result of a past event, it is probable that the charity will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

**Judgements**

The charity considers on an annual basis the judgements that are made by management when applying its significant accounting policies that would have the most significant effect on amounts that are recognised in the financial statements. The trustees consider there are no such significant judgements.

**SEPSIS RESEARCH (FEAT) SCIO**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025**

**2. DONATIONS AND LEGACIES**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Donations	25,336	22,451
Gift aid	21,490	15,084
Community fundraising	116,904	222,582
Trusts and foundations	135,442	71,650
Corporate - sponsorship	9,064	4,712
In memory	21,007	16,364
Donated services and facilities	18,420	16,540
PPIE	1,525	-
	<u>349,188</u>	<u>369,383</u>

**3. OTHER TRADING ACTIVITIES**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Sales	888	1,576
	<u>888</u>	<u>1,576</u>

**4. INVESTMENT INCOME**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Deposit account interest	1,573	462
	<u>1,573</u>	<u>462</u>

**5. RAISING FUNDS**

**Raising donations and legacies**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Fundraising	79,287	61,496
	<u>79,287</u>	<u>61,496</u>

**6. CHARITABLE ACTIVITIES COSTS**

	<b>Direct Costs</b>	<b>Grant funding of activities (see note 7)</b>	<b>Support costs (see note 8)</b>	<b>Totals</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Charitable activities	166,322	81,214	31,539	279,075
	<u>166,322</u>	<u>81,214</u>	<u>31,539</u>	<u>279,075</u>

**SEPSIS RESEARCH (FEAT) SCIO**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025**

**7. GRANTS PAYABLE**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Charitable activities	<b>81,214</b>	93,049

The total grants paid to institutions during the year was as follows:

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
University of Edinburgh	<b>17,200</b>	60,236
NHS Greater Glasgow & Clyde	-	11,100
University of Strathclyde	<b>20,000</b>	-
James Lind Alliance	<b>21,130</b>	21,713
University of Cambridge	<b>3,000</b>	-
University of Birmingham	<b>9,884</b>	-
University College London	<b>10,000</b>	-
	<b>81,214</b>	93,049

**8. SUPPORT COSTS**

	<b>Governance costs</b>
	<b>£</b>
Charitable activities	<b>31,539</b>

Support costs, included in the above, are as follows:

	<b>2025</b>	<b>2024</b>
	<b>Charitable activities</b>	<b>Total activities</b>
	<b>£</b>	<b>£</b>
Insurance	<b>622</b>	<b>765</b>
Consultancy fees	<b>26,460</b>	<b>26,460</b>
Independent examiner's fee	<b>2,028</b>	<b>1,890</b>
Travel	<b>2,429</b>	<b>1,851</b>
	<b>31,539</b>	<b>30,966</b>

**9. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

**SEPSIS RESEARCH (FEAT) SCIO**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025**

**9. TRUSTEES' REMUNERATION AND BENEFITS - continued**

**Trustees' expenses**

During the year, there were trustees' expenses of £878 paid to 4 trustees (2024: £Nil).

**10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	<b>Unrestricted funds £</b>	<b>Restricted funds £</b>	<b>Total funds £</b>
<b>INCOME FROM</b>			
Donations and legacies	331,283	38,100	369,383
Other trading activities	1,576	-	1,576
Investment income	462	-	462
<b>Total</b>	<u>333,321</u>	<u>38,100</u>	<u>371,421</u>
<b>EXPENDITURE ON</b>			
Raising funds	61,496	-	61,496
<b>Charitable activities</b>			
Charitable activities	198,870	93,049	291,919
<b>Total</b>	<u>260,366</u>	<u>93,049</u>	<u>353,415</u>
<b>NET INCOME/(EXPENDITURE)</b>	72,955	(54,949)	18,006
<b>Transfers between funds</b>	<u>(2,440)</u>	<u>2,440</u>	<u>-</u>
<b>Net movement in funds</b>	70,515	(52,509)	18,006
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	97,556	52,509	150,065
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u><u>168,071</u></u>	<u><u>-</u></u>	<u><u>168,071</u></u>

**11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2025 £</b>	<b>2024 £</b>
Trade debtors	500	-
Other debtors	637	229
	<u><u>1,137</u></u>	<u><u>229</u></u>

**SEPSIS RESEARCH (FEAT) SCIO**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025**

**12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2025 £	2024 £
Trade creditors	65	-
Accruals and deferred income	3,702	3,331
	<u>3,767</u>	<u>3,331</u>

**13. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
Current assets	141,625	23,500	165,125	171,402
Current liabilities	(3,767)	-	(3,767)	(3,331)
	<u>137,858</u>	<u>23,500</u>	<u>161,358</u>	<u>168,071</u>

**14. MOVEMENT IN FUNDS**

	At 1/4/24 £	Net movement in funds £	Transfers between funds £	At 31/3/25 £
<b>Unrestricted funds</b>				
General fund	108,071	28,516	1,271	137,858
Research Awards	60,000	(58,729)	(1,271)	-
	<u>168,071</u>	<u>(30,213)</u>	-	<u>137,858</u>
<b>Restricted funds</b>				
Awareness Campaign Northern Ireland	-	12,500	-	12,500
Maternal Sepsis England	-	5,000	-	5,000
Maternal Sepsis Scotland	-	6,000	-	6,000
	<u>-</u>	<u>23,500</u>	-	<u>23,500</u>
<b>TOTAL FUNDS</b>	<u>168,071</u>	<u>(6,713)</u>	<u>-</u>	<u>161,358</u>

SEPSIS RESEARCH (FEAT) SCIO

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2025

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	271,757	(243,241)	28,516
Research Awards	-	(58,729)	(58,729)
	<u>271,757</u>	<u>(301,970)</u>	<u>(30,213)</u>
<b>Restricted funds</b>			
Research Awards	30,360	(30,360)	-
Awareness Campaign Northern Ireland	19,532	(7,032)	12,500
Maternal Sepsis England	15,000	(10,000)	5,000
Maternal Sepsis Scotland	15,000	(9,000)	6,000
	<u>79,892</u>	<u>(56,392)</u>	<u>23,500</u>
<b>TOTAL FUNDS</b>	<u><u>351,649</u></u>	<u><u>(358,362)</u></u>	<u><u>(6,713)</u></u>

Comparatives for movement in funds

	At 1/4/23 £	Net movement in funds £	Transfers between funds £	At 31/3/24 £
<b>Unrestricted funds</b>				
General fund	97,556	72,955	(62,440)	108,071
Research Awards	-	-	60,000	60,000
	<u>97,556</u>	<u>72,955</u>	<u>(2,440)</u>	<u>168,071</u>
<b>Restricted funds</b>				
Research Awards	52,509	(54,949)	2,440	-
	<u>52,509</u>	<u>(54,949)</u>	<u>2,440</u>	<u>-</u>
<b>TOTAL FUNDS</b>	<u><u>150,065</u></u>	<u><u>18,006</u></u>	<u><u>-</u></u>	<u><u>168,071</u></u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	333,321	(260,366)	72,955
<b>Restricted funds</b>			
Research Awards	38,100	(93,049)	(54,949)
	<u>38,100</u>	<u>(93,049)</u>	<u>(54,949)</u>
<b>TOTAL FUNDS</b>	<u><u>371,421</u></u>	<u><u>(353,415)</u></u>	<u><u>18,006</u></u>

## **SEPSIS RESEARCH (FEAT) SCIO**

### **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025**

#### **14. MOVEMENT IN FUNDS - continued**

##### **General fund**

The general funds are available for use at the discretion of the Trustees in accordance with the charity's objectives. It is maintained at a level sufficient to allow the organisation time to adjust to changing financial circumstances.

##### **Designated - Research Awards**

The designated funds are amounts set aside by the board for grant awards in the forthcoming year.

##### **Restricted - Research Awards**

The restricted funds are amounts which are specified for a certain purpose by the provider.

##### **Restricted - Awareness Campaign Northern Ireland**

The restricted funds are amounts which are specified for a certain purpose by the provider.

##### **Restricted - Maternal Sepsis England**

The restricted funds are amounts which are specified for a certain purpose by the provider.

##### **Restricted - Maternal Sepsis Scotland**

The restricted funds are amounts which are specified for a certain purpose by the provider.

#### **15. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 March 2025 nor for the year ended 31 March 2024.